Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies

Greenberg, 2003, The economic burden of depression in the United States: How did it change between 1990 and 2000?, J Clin Psychiatry, 64, 1465, 10.4088/JCP.v64n1211 Moussavi, 2007, Depression, chronic diseases, and decrements in health: Results from the World Health Surveys, Lancet, 370, 851, 10.1016/S0140-6736(07)61415-9 Rush, 2004, Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design, Control Clin Trials., 25, 119, 10.1016/S0197-2456(03)00112-0 Fava, 1996, Definition and epidemiology of treatment resistant depression, Psychiatr Clin North Am., 19, 179, 10.1016/S0193-953X(05)70283-5 Trivedi, 2006, Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice, Am J Psychiatry, 163, 28, 10.1176/appi.ajp.163.1.28 Khan, 2002, Severity of depression and response to antidepressants and placebo: An analysis of the Food and Drug Administration database, J Clin Psychopharmacol., 22, 40, 10.1097/00004714-200202000-00007 Deecher, 2006, Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor, J Pharmacol Exp Ther., 318, 657, 10.1124/jpet.106.103382 2008 DeMartinis, 2007, A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder, J Clin Psychiatry, 68, 677, 10.4088/JCP.v68n0504 Septien-Velez, 2007, A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder, Int Clin Psychopharmacol., 22, 338, 10.1097/YIC.0b013e3281e2c84b Boyer, 2008, Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial, Int Clin Psychopharmacol., 23, 243, 10.1097/YIC.0b013e32830cebed Liebowitz, 2008, Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder, Curr Med Res Opin., 24, 1877, 10.1185/03007990802161923 Sheehan, 1998, The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10, J Clin Psychiatry, 59, 22 1994 Hamilton, 1960, A rating scale for depression, J Neurol Neurosurg Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 1976, Clinical Global Impressions, 217 Montgomery, 1979, A new depression scale designed to be sensitive to change, Br J Psychiatry, 134, 382, 10.1192/bjp.134.4.382 Bech, 1975, Quantitative rating of depressive states, Acta Psychiatr Scand., 51, 161, 10.1111/j.1600-0447.1975.tb00002.x Rosenbaum, 1998, Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial, Biol Psychiatry, 44, 77, 10.1016/S0006-3223(98)00126-7 2004 Molenberghs, 2004, Analyzing incomplete longitudinal clinical trial data, Biostatistics, 5, 445, 10.1093/biostatistics/kxh001 Mallinckrodt, 2004, The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA, Clin Trials., 1, 477, 10.1191/1740774504cn049oa Detke, 2002, Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial, J Clin Psychiatry, 63, 308, 10.4088/JCP.v63n0407 Detke, 2002, Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression, J Psychiatr Res., 36, 383, 10.1016/S0022-3956(02)00060-2 Brannan, 2005, Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder, J Psychiatr Res., 39, 43, 10.1016/j.jpsychires.2004.04.011 2004 2007 Turner, 2008, Selective publication of antidepressant trials and its influence on apparent efficacy, N Engl J Med., 358, 252, 10.1056/NEJMsa065779 Khan, 2003, Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: An analysis of the Food and Drug Administration summary basis of approval reports, Neuropsychopharmacology, 28, 552, 10.1038/sj.npp.1300059 Walsh, 2002, Placebo response in studies of major depression: Variable, substantial, and growing, JAMA, 287, 1840, 10.1001/jama.287.14.1840 Papakostas, 2009, Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD, Eur Neuropsychopharmacol., 19, 34, 10.1016/j.euroneuro.2008.08.009 Sotsky, 1991, Patient predictors of response to psychotherapy and pharmacotherapy: Findings in the NIMH Treatment of Depression Collaborative Research Program, Am J Psychiatry, 148, 997, 10.1176/ajp.148.8.997 Kirsch